PCM
LEGN icon

Prelude Capital Management’s Legend Biotech LEGN Stock Holding History

Prelude Capital Management’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-13,009
Closed -$783K – 1441
2023
Q4 		$783K Buy
13,009
+2,687
+26% +$170K 0.05% 366
2023
Q3 		$693K Buy
10,322
+5,500
+114% +$382K 0.05% 384
2023
Q2 		$333K Sell
4,822
-11,178
-70% -$730K 0.02% 597
2023
Q1 		$772K Sell
16,000
-5,600
-26% -$274K 0.05% 358
2022
Q4 		$1.08M Buy
21,600
+3,600
+20% +$174K 0.06% 355
2022
Q3 		$734K Hold
18,000
– – 0.03% 515
2022
Q2 		$990K Buy
18,000
+350
+2% +$14.8K 0.03% 527
2022
Q1 		$641K Buy
+17,650
New +$697K 0.02% 739

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Prelude Capital Management's LEGN Position: Q1 2024 in Review

Prelude Capital Management sold out of Legend Biotech (LEGN) in Q1 2024, closing a stake of 13,009 shares — an estimated $783K sold.

Prelude Capital Management first reported a position in LEGN in Q1 2022 and held it in 8 quarters. The position peaked at $1.08M in Q4 2022. 192 funds tracked by Wall St. Rank hold LEGN as of Q1 2024.

  • Prelude Capital Management reported no remaining Legend Biotech position as of Q1 2024 after selling out during the quarter.
  • Prelude Capital Management sold 13,009 Legend Biotech shares in Q1 2024, an estimated $783K.
  • Prelude Capital Management first reported a position in Legend Biotech in Q1 2022 and held it in 8 quarters.
  • Prelude Capital Management's Legend Biotech position peaked at $1.08M in Q4 2022.
  • 192 funds tracked by Wall St. Rank held Legend Biotech as of Q1 2024.

Based on Prelude Capital Management's 13F filing for Q1 2024, filed 15 May 2024.